economy
March 13, 2026
Trump's MFN policy threatens US competitiveness with China
Congressional enactment of the “most favored nation” drug pricing policy urged by President Donald Trump in his State of the Union message would gravely harm American innovation, competitiveness, and national security in the emerging pharmaceutical technology race with China by crippling the market incentive system that has reliably propelled U.S. global leadership in this vital sector for decades.
TL;DR
- The "most favored nation" (MFN) drug pricing policy, advocated by President Trump, is criticized for potentially harming American innovation, competitiveness, and national security.
- MFN policies cap prescription drug costs in the U.S. based on the lowest prices charged internationally, a concept previously explored by various administrations and legislative bodies.
- Economic analyses suggest that MFN price controls would significantly reduce investment in pharmaceutical research and development (R&D), leading to fewer new drug approvals.
- China's strategic investment and rapid growth in the pharmaceutical sector, driven by aggressive industrial policies, position it as a significant rival to U.S. leadership.
- The imposition of MFN pricing could exacerbate U.S. dependence on Chinese production and supply chains for critical ingredients, posing national security risks.
- The article suggests focusing on alternative solutions, such as international trade negotiations to address drug pricing, rather than implementing MFN policies.
Continue reading the original article